ArticleImmunology2009
Type I Streptococcus pneumoniae carbohydrate utilizes a nitric oxide and MHC II-dependent pathway for antigen presentation.
Article in Immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 69 citations in OpenAlex.
- Harnessing the Power of Our Immune System: The Antimicrobial and Antibiofilm Properties of Nitric Oxide.Microorganisms · 2024Review
- Mechanisms of Formation of Antibodies against Blood Group Antigens That Do Not Exist in the Body.International journal of molecular sciences · 2023Article
- An Archetypical Model for EngraftingMicroorganisms · 2023Article
- Chemical Reporters for Bacterial Glycans: Development and Applications.Chemical reviews · 2022Review
- The Intestinal Commensal, Bacteroides fragilis, Modulates Host Responses to Viral Infection and Therapy: Lessons for Exploration during Mycobacterium tuberculosis Infection.Infection and immunity · 2022Review
- Discovery of Semi- and Fully-Synthetic Carbohydrate Vaccines Against Bacterial Infections Using a Medicinal Chemistry Approach.Chemical reviews · 2021Review
- Emergence and significance of carbohydrate-specific antibodies.Genes and immunity · 2020Review
- The History of Carbohydrates in Type I Allergy.Frontiers in immunology · 2020Review
- Complementary Role of CD4+ T Cells in Response to Pneumococcal Polysaccharide Vaccines in Humans.Vaccines · 2019Review
- The Structural Complexity and Animal Tissue Distribution ofFrontiers in molecular biosciences · 2019Review
- Diverse Intestinal Bacteria Contain Putative Zwitterionic Capsular Polysaccharides with Anti-inflammatory Properties.Cell host & microbe · 2016Article
- Carbohydrates as T-cell antigens with implications in health and disease.Glycobiology · 2016Review
- Dendritic cell-specific Mgat2 knockout mice show antigen presentation defects but reveal an unexpected CD11c expression pattern.Glycobiology · 2016Article
- Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune Responses.Vaccines · 2016Review
- Bacterial capsular polysaccharide prevents the onset of asthma through T-cell activation.Glycobiology · 2015Article
- Polysaccharide A from the capsule of Bacteroides fragilis induces clonal CD4+ T cell expansion.The Journal of biological chemistry · 2015Article
- Elucidating Structural Features of an Entirely Carbohydrate Cancer Vaccine Construct Employing Circular Dichroism and Fluorescent Labeling.MedChemComm · 2014Article
- Mgat2 ablation in the myeloid lineage leads to defective glycoantigen T cell responses.Glycobiology · 2014Article
- Article
- Nitric oxide and KLF4 protein epigenetically modify class II transactivator to repress major histocompatibility complex II expression during Mycobacterium bovis bacillus Calmette-Guerin infection.The Journal of biological chemistry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Some pathogenic bacteria form thick capsules that both block immune responses through inhibition of complement deposition and phagocytosis and stimulate a weak response resulting from a lack of T-cell involvement. Contrary to this model, capsular polysaccharides from 23 serotypes of Streptococcus pneumoniae have been successfully used in a multivalent vaccine in the absence of a carrier protein. Furthermore, type I pneumococcal polysaccharide (Sp1) has been shown to activate T cells in vivo and in vitro via an uncharacterized mechanism. In the present report, we demonstrate that Sp1 utilizes the major histocompatibility complex (MHC) class II pathway in antigen-presenting cells (APCs) for processing and presentation. APCs internalize and process Sp1 through a nitric oxide-dependent mechanism and, once inside the cell, it associates with MHC II proteins in an H-2M-dependent manner that leads to in vivo T-cell activation. These results establish that Sp1 activates T cells which can lead to abscess formation in mice through an H-2M-dependent polysaccharide antigen presentation pathway in APCs, potentially contributing to pneumococcal polysaccharide vaccine efficacy through the recruitment of T-cell help.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.